Multiple primary melanomas (MPMs) and criteria for genetic assessment: MultiMEL, a multicenter study of the Italian Melanoma Intergroup

• Published in: Journal of the American Academy of Dermatology Vol. 74; no. 2; pp. 325 - 332
• Main Authors: Bruno, William, Pastorino, Lorenza, Ghiorzo, Paola, Andreotti, Virginia, Martinuzzi, Claudia, Menin, Chiara, Elefanti, Lisa, Stagni, Camilla, Vecchiato, Antonella, Rodolfo, Monica, Maurichi, Andrea, Manoukian, Siranoush, De Giorgi, Vincenzo, Savarese, Imma, Gensini, Francesca, Borgognoni, Lorenzo, Testori, Alessandro, Spadola, Giuseppe, Mandalà, Mario, Imberti, Gianlorenzo, Savoia, Paola, Astrua, Chiara, Ronco, Anna Maria, Farnetti, Alessandra, Tibiletti, Maria Grazia, Lombardo, Maurizio, Palmieri, Giuseppe, Ayala, Fabrizio, Ascierto, Paolo, Ghigliotti, Giovanni, Muggianu, Marisa, Spagnolo, Francesco, Picasso, Virginia, Tanda, Enrica Teresa, Queirolo, Paola, Bianchi-Scarrà, Giovanna
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.02.2016
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; cyclin-dependent kinase; Cyclin-Dependent Kinase 4 - genetics; cyclin-dependent kinase inhibitor 2A; Cyclin-Dependent Kinase Inhibitor p16 - genetics; Dermatology; family history; genetic assessment; Genetic Counseling; Germ-Line Mutation; Humans; Italy; melanoma; Melanoma - genetics; microphthalmia-associated transcription factor; Microphthalmia-Associated Transcription Factor - genetics; Middle Aged; mutation; Mutation Rate; Neoplasms, Multiple Primary - genetics; pancreatic cancer; Patient Selection; Skin Neoplasms - genetics; Young Adult; Italy; SIGU; cyclin-dependent kinase inhibitor 2A; CDKN2A; genetic assessment; melanoma; MITF; CDK; MPM; microphthalmia-associated transcription factor; mutation; SPM; pancreatic cancer; family history; cyclin-dependent kinase; Italian Society of Human Genetics; multiple primary melanoma; single primary melanoma

Multiple primary melanoma (MPM), in concert with a positive family history, is a predictor of cyclin-dependent kinase (CDK) inhibitor 2A (CDKN2A) germline mutations. A rule regarding the presence of either 2 or 3 or more cancer events (melanoma and pancreatic cancer) in low or high melanoma incidenc...